

Response Under 37 CFR 1.116, Expedited Procedure
Examining Group 1600
Application No. 09/242,772
Paper dated June 25, 2004
In reply to USPTO correspondence of February 25, 2004
Attorney Docket No. 3374-990278

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

Claims 1-52 (Cancelled).

Claim 53 (New): An isolated nucleic acid sequence consisting of 7313 base pairs as depicted in Figure 4A or consisting of the open reading frame of 1500 base pairs starting with the ATG at position 481-483 as depicted in Figure 4A, wherein said open reading frame encodes for a pleomorphic adenoma gene 1 (PLAG1) protein.

Claim 54 (New): An isolated hybrid nucleic acid sequence consisting of a fragment of the nucleic acid sequence according to claim 53 fused to a nucleic acid sequence derived from a translocation partner of PLAG1, wherein the presence of said hybrid nucleic acid sequence allows the diagnosis of a cell containing said hybrid nucleic acid sequence as a tumor cell.

Claim 55 (New): An isolated nucleic acid sequence according to claim 54, wherein said translocation partner is a CTNNB1 protein.

Claim 56 (New): An isolated nucleic acid sequence according to claim 55 containing 509 base pairs corresponding to exon 1 of CTNNB1 fused to exons 3 to 5 of PLAG1.

Claim 57 (New): An isolated nucleic acid sequence according to claim 55 containing 614 base pairs corresponding to exon 1 of CTNNB1 fused to exons 2 to 5 of PLAG1.

Response Under 37 CFR 1.116, Expedited Procedure
Examining Group 1600
Application No. 09/242,772
Paper dated June 25, 2004
In reply to USPTO correspondence of February 25, 2004
Attorney Docket No. 3374-990278

Claim 58. (New): An isolated anti-sense nucleic acid sequence of the nucleic acid sequence according to claim 53 or fragments thereof which inhibit the expression of said nucleic acid sequence according to claim 53 in tumor cells.